http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2014002105-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c6eb1154b7f60c152d3936676eb2eca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4453 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 |
| filingDate | 2012-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_208082794277ac7b0276f719727e0e67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f595e97f3aff8bc63baa6aeccc2a77c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53ae2a78065401999d47abd01faca26f |
| publicationDate | 2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2014002105-A |
| titleOfInvention | STROGEN RECEIVER LINKS AND METHODS OF USE OF THE SAME. |
| abstract | The present invention relates to methods for reducing testosterone levels through the reduction of luteinizing hormone (LH) or independent of LH levels in a male subject, and methods for treating, suppressing, reducing incidence, reducing severity, or inhibit prostate cancer, advanced prostate cancer (5), castration-resistant prostate cancer (CRPC), metastatic castration-resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration-resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC), and methods to reduce high or increasing levels of PSA and / or increase SHBG levels in a subject suffering from advanced prostate cancer , castration-resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (10) (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castration levels secondary to ADT and reduce high or increasing levels of PSA. |
| priorityDate | 2011-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 567.